The Story

A vial of grey-market peptide has a longer journey behind it than most of the people injecting it realise. It usually begins as bulk powder in a Chinese chemical plant, the kind that runs around the clock and will synthesise more or less any compound you can name. From there it passes through online vendors, shipped in plain packets marked “for research use only,” paid for in Bitcoin, and vouched for by a lab report the buyer has learned to scrutinise line by line. None of it touches a pharmacy. Almost none of it is what a regulator would call a medicine.

Who Makes It

The factories themselves are not mysterious. China’s chemical sector makes the world’s research peptides the way it makes everything else, at scale and cheaply, and a “for research use only” label keeps the whole trade just outside the reach of drug regulators. What unsettles even people inside the market is where some of those factories came from. Chainalysis, tracing payments across the blockchain, has linked several of the busiest peptide vendors to Chinese manufacturers that used to sell precursor chemicals to drug cartels, the raw ingredients for fentanyl and synthetic stimulants. One named supplier had advertised on underground forums, complete with notes on how to clear customs. The buyers changed; a looksmaxxing crowd chasing muscle and youth replaced the cartels. A good deal of the chemistry, and the chemists, did not.

The Loophole and the Rails

Two things keep the trade moving: language and crypto. Compounds enter the United States stamped “not for human consumption,” which exempts them from the approval a real medicine would need, even though everyone involved knows exactly what they are for; by 2025 they were turning up on Temu. The money runs on Bitcoin and stablecoins. Chainalysis put the sector past a $100 million annual run rate, with crypto flowing to vendor wallets jumping from $12 million in the last quarter of 2025 to $32 million in the first of 2026. Customs has noticed: seizures are climbing, yet Chinese peptide imports to the US roughly doubled to $328 million in 2025, which suggests the seizures catch only a sliver of the flow.

Who Checks It

With no regulator standing behind any of this, the market built its own quality control, and it rests almost entirely on one independent lab. Janoshik Analytical, running samples through high-performance liquid chromatography, has become the closest thing the grey market has to an inspector. Vendors send it batches; it posts the results by batch number on its own servers, where a buyer can look them up and a seller cannot quietly bury a bad one. The findings are not reassuring. By one tally of Janoshik’s 2024 results, roughly 43 per cent of peptides missed the purity their labels claimed, with weaker vendors shipping product that ran 71 to 91 per cent pure against a stated 99. The lab holds no formal accreditation, and its raw data sits behind a paywall. In a trade with nothing better, it is treated as good enough.

The Caveat

Reporting how this market works is not a nod to using it, and the gaps are exactly where the danger sits. The compounds arrive as raw powder, and even a clean Janoshik certificate speaks only to the batch that was tested, and tells you nothing about the vial that actually lands on the doorstep. The evidence underneath the most popular products is thin: BPC-157, the so-called wolverine peptide, rests on three small human studies totalling fewer than thirty people, and no controlled trials at all. We can tell you, compound by compound, what the research does and does not show, and we will. We will not tell you where to buy anything or how to dose it. That boundary is the difference between covering this story and joining it.

What’s Next

Pressure is the one certainty. The FDA has moved against compounded GLP-1s, customs is screening harder, and the named Chinese suppliers will be tracked across the same blockchain that exposed them. None of that tends to shut a market this size; it pushes it further into the dark, toward private channels and fresh shell companies. The more interesting question is whether the buyers force a clean-up from below. If enough of them keep refusing to touch an untested batch, the vendors who test honestly start to win, and the grey market backs awkwardly into the quality control no regulator ever imposed. It would be a strange way to make a drug supply safer, and quite possibly the only one on offer.